Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy

[1]  Peng Huang,et al.  Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy , 2022, Journal of Hematology & Oncology.

[2]  M. Ciborowski,et al.  Proteomics and metabolomics approach in adult and pediatric glioma diagnostics. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[3]  J. Esteve,et al.  European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol , 2021, Blood advances.

[4]  R. Kanagal-Shamanna,et al.  Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies , 2021, Frontiers in Oncology.

[5]  S. Baker,et al.  Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML , 2021, Molecular Cancer Therapeutics.

[6]  Junshik Hong,et al.  Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples , 2021, Metabolites.

[7]  M. Konopleva,et al.  The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells , 2021, Frontiers in Oncology.

[8]  J. Nikliński,et al.  The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied , 2021, Cancers.

[9]  G. Castellani,et al.  Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations , 2021, Leukemia.

[10]  J. Guingab-Cagmat,et al.  Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML , 2021, Frontiers in Oncology.

[11]  G. Borthakur,et al.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm , 2021, Blood Cancer Journal.

[12]  F. Fauvelle,et al.  The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. , 2021, Blood advances.

[13]  T. Uehara,et al.  Serum sphingomyelin species profile is altered in hematologic malignancies. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[14]  M. Loda,et al.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. , 2020, Advanced drug delivery reviews.

[15]  V. Nachiappan,et al.  Crosstalk between protein N-glycosylation and lipid metabolism in Saccharomyces cerevisiae , 2019, Scientific Reports.

[16]  R. Levine,et al.  Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. , 2019, Blood advances.

[17]  Matthew R. MacDougall,et al.  Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells , 2019, Journal of Lipid Research.

[18]  M. Pischetsrieder,et al.  Quantification of 24 circulating endocannabinoids, endocannabinoid-related compounds, and their phospholipid precursors in human plasma by UHPLC-MS/MS[S] , 2019, Journal of Lipid Research.

[19]  G. Garcia-Manero,et al.  Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis , 2019, Cancer communications.

[20]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2019, Cancer cell.

[21]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[22]  W. Fiedler,et al.  Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression , 2018, Cellular & Molecular Immunology.

[23]  S. Meshinchi,et al.  Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia , 2018, Scientific Reports.

[24]  E. Clappier,et al.  The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.

[25]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[26]  M. Andreeff,et al.  Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. , 2016, Blood.

[27]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[28]  L. Riboni,et al.  Sphingolipids: Key Regulators of Apoptosis and Pivotal Players in Cancer Drug Resistance , 2014, International journal of molecular sciences.

[29]  Junmin Li,et al.  Rapid diagnosis and prognosis of de novo acute myeloid leukemia by serum metabonomic analysis. , 2013, Journal of proteome research.

[30]  Yu Wang,et al.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. , 2013, Blood.

[31]  W. Jędrzejczak,et al.  Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Maggiolini,et al.  Glycerophospholipid synthesis as a novel drug target against cancer. , 2011, Current molecular pharmacology.

[33]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[34]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[35]  A. Llebaria,et al.  Inhibitors of sphingolipid metabolism enzymes. , 2006, Biochimica et biophysica acta.

[36]  R. Christopherson,et al.  Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. , 2004, Leukemia research.

[37]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[39]  OUP accepted manuscript , 2022, International Immunology.

[40]  D. Steinhilber,et al.  How to effectively treat acute leukemia patients bearing MLL-rearrangements ? , 2018, Biochemical pharmacology.